Drug intelligence / Profile preview

Ad4-Env145NFL

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

Ad4-Env145NFL is an investigational HIV vaccine that uses a live adenovirus vector (Ad4) to deliver HIV envelope proteins. It is administered intranasally as a liquid spray and is designed to stimulate an immune response against HIV. The vaccine contains genetically modified adenovirus that produces pieces of protein from the HIV virus, specifically the Env145NFL protein. As the virus reproduces, it may cause an immune response to both adenovirus and to HIV proteins. This vaccine is being studied in combination with other HIV vaccines in heterologous prime-boost regimens.

Beyond the preview

Go deeper on Ad4-Env145NFL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ad4-Env145NFL.

Explore the full profile